enGene
ENGNPhase 2enGene is a Canadian biotech focused on creating a new class of genetic medicines using its proprietary non-viral gene delivery platform. The company's lead program, EG-70, is in clinical development for non-muscle invasive bladder cancer (NMIBC), aiming to overcome the limitations of current viral vector-based therapies. enGene leverages its platform to target mucosal tissues with high efficiency and localized effect, potentially addressing a range of diseases. The company went public in 2023 to fund its clinical advancement and platform expansion.
ENGN · Stock Price
Historical price data
AI Company Overview
enGene is a Canadian biotech focused on creating a new class of genetic medicines using its proprietary non-viral gene delivery platform. The company's lead program, EG-70, is in clinical development for non-muscle invasive bladder cancer (NMIBC), aiming to overcome the limitations of current viral vector-based therapies. enGene leverages its platform to target mucosal tissues with high efficiency and localized effect, potentially addressing a range of diseases. The company went public in 2023 to fund its clinical advancement and platform expansion.
Technology Platform
Proprietary non-viral gene delivery platform using engineered dextran-derived complexes (DDX) for localized, efficient transfection of mucosal tissues.
Pipeline Snapshot
11 drug in pipeline
| Drug | Indication | Stage |
|---|---|---|
| EG-70 (phase 1) + EG-70 (phase 2) | Superficial Bladder Cancer | Phase 1/2 |
Funding History
4Total raised: $370M
Opportunities
Risk Factors
Competitive Landscape
Main competitors in NMIBC include Merck's Keytruda and Ferring's Adstiladrin. enGene differentiates through its non-viral, localized delivery platform, which may offer improved safety and repeat dosing potential compared to viral gene therapies and systemic immunotherapies.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile